Association between endothelial dysfunction and frailty: the Toledo Study for Healthy Aging

Area of Science:

• Gerontology
• Cardiology
• Vascular Biology

Background:

• Cardiovascular disease (CVD) is implicated in frailty, but the role of early-stage CVD, such as endothelial dysfunction, remains unclear.
• Endothelial dysfunction, a precursor to clinical CVD, affects vascular health and may contribute to the development of frailty.

Purpose of the Study:

• To investigate the association between endothelial dysfunction, quantified by asymmetric dimethylarginine (ADMA) levels, and frailty in an elderly cohort.
• To explore potential interactions between ADMA, atherosclerotic disease, and frailty.

Main Methods:

• Prospective cohort study (Toledo Study for Healthy Aging) including 1287 community-dwelling elderly individuals.
• Asymmetric dimethylarginine (ADMA) levels measured via enzyme immunoassay.
• Frailty assessed using established criteria; logistic regression used to analyze associations, adjusting for confounders and atherosclerotic disease (ankle-brachial index).

Main Results:

• Higher ADMA levels were observed in frail individuals compared to non-frail individuals.
• A significant interaction was found between ADMA and atherosclerotic disease concerning frailty risk (p=0.045).
• Increased ADMA levels were associated with a higher risk of frailty in subjects without atherosclerotic disease (OR=1.14; 95% CI: 1.01–1.28, p=0.032), but not in those with it.

Conclusions:

• Endothelial dysfunction, indicated by elevated ADMA levels, is associated with frailty in the elderly.
• These findings suggest that early vascular impairment plays a significant role in the pathogenesis of frailty.